Cooperative Agreement UH2CA286583
Award Date
9/5/24
Completion Date
8/31/26
Dollars Obligated
$258K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $179,988 to the University of Utah to conduct research on the role of dietary lipids in accelerating breast cancer tumor growth, particularly in the context of obesity. The key objectives are to: Determine if breast cancer cells preferentially utilize dietary lipids over glucose in lipid-rich environments, such as those found in obesity. Trace the metabolic fate of...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Biology Research" (CFDA 93.396), provides $640,760 to The Leland Stanford Junior University to conduct comprehensive research on the fundamental biological mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) metastasis, organ tropism, and immune evasion. The key products and services to be delivered through this 5-year project include: 1) employing molecular...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $693,075 to Yale University to conduct research on how incretin mimetics, a class of anti-obesity medications, may impact the development of pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of pancreatic cancer. The award supports a 5-year project to determine whether and how incretin mimetics, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs),...
The National Cancer Institute (NCI) awarded a $737,444 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Hawaii to conduct research aimed at "Uncovering Causal Protein Markers to Characterize Pancreatic Cancer Etiology and Improve Risk Prediction." The project seeks to: 1) identify putative causal protein biomarkers for pancreatic ductal adenocarcinoma (PDAC) risk using novel research methods; 2) functionally characterize...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $624,518 in funding to the University of South Florida to conduct research on the role of arachidonic acid metabolism in modulating the tumor immune microenvironment for colorectal cancer. The project aims to: 1) analyze arachidonic acid pathway lipid mediators in a large reference set of clinically-curated colorectal cancer samples to understand their relationship to immune...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...